Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group nucleosome-binding domain-containing protein 1 (HMGN1) is a small, non-histone chromosomal protein that binds specifically to nucleosomes and influences chromatin structure. It modulates histone post-translational modifications and plays a key role in regulating gene expression, chromatin accessibility, and cellular differentiation. HMGN1 is ubiquitously expressed, most highly during early development and in stem cell populations, and is downregulated as cells differentiate. Loss of HMGN1 impairs responses to DNA damage and cellular stress, leading to increased tumorigenic potential and sensitivity to ionizing or UV radiation. Although HMGN1 strongly affects cell fate and gene regulation, it is not a classical pharmacological target and no drugs directly interact with it
Null. No direct drugs or small molecules have reported mechanisms of action via targeting HMGN1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group nucleosome-binding domain-containing protein 1 (HMGN1).